Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving NivolumabSuzanne L. Topalian, F. Stephen Hodi, Mario Sznol et al.|Journal of Clinical Oncology|2014Cited by 2.2k
Myocarditis in Patients Treated With Immune Checkpoint InhibitorsSyed Mahmood, Tomas G. Neilan, Michael G. Fradley et al.|Journal of the American College of Cardiology|2018Cited by 1.5k
Resistance to checkpoint blockade therapy through inactivation of antigen presentationMoshe Sade-Feldman, Nir Hacohen, Yunxin J. Jiao et al.|Nature Communications|2017Cited by 999
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic MelanomaDennie T. Frederick, Jennifer A. Wargo, Adriano Piris et al.|Clinical Cancer Research|2013Cited by 938
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune DisordersDouglas B. Johnson, Joseph I. Clark, Fei Ye et al.|JAMA Oncology|2015Cited by 656